All In Biotech

NDA 022410 · Indivior

Suboxone

Buprenorphine Hydrochloride, Naloxone Hydrochloride · Buccal, Sublingual

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Aug 30, 2010

Approved uses

5

Original approval plus efficacy supplements

Registered trials

512

125 Phase 3, 43 recruiting

FAERS reports

24,312

15,334 serious, 1,271 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 22, 2025.

SUBOXONE sublingual film is indicated for treatment of opioid dependence. SUBOXONE sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. SUBOXONE® sublingual film contains buprenorphine, a partial‐opioid agonist, and naloxone, an opioid antagonist, and is indicated for treatment of opioid dependence. ( 1 ) SUBOXONE sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

Mechanism: SUBOXONE sublingual film contains buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • SUBOXONE · BUPRENORPHINE HYDROCHLORIDE EQ 12MG BASE; NALOXONE HYDROCHLORIDE EQ 3MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription · TE AB
  • SUBOXONE · BUPRENORPHINE HYDROCHLORIDE EQ 8MG BASE; NALOXONE HYDROCHLORIDE EQ 2MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription · TE AB
  • SUBOXONE · BUPRENORPHINE HYDROCHLORIDE EQ 4MG BASE; NALOXONE HYDROCHLORIDE EQ 1MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription · TE AB
  • SUBOXONE · BUPRENORPHINE HYDROCHLORIDE EQ 2MG BASE; NALOXONE HYDROCHLORIDE EQ 0.5MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.

All 512 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence4,326
  • drug withdrawal syndrome3,371
  • pain2,574
  • off label use2,109
  • overdose1,871
  • nausea1,664
  • emotional distress1,485
  • anxiety1,371
  • vomiting1,350
  • drug abuse1,132
  • headache1,129
  • insomnia1,089

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200533
2006103
2007163
2008239
2009442
20101,163
20111,071
2012835
2013504
20142,267
20152,187
20161,723
20171,850
20181,690
20191,265
20201,804
20212,628
20221,483
2023838
2024637
2025788
2026580

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Suboxone (Buprenorphine HCl/Naloxone HCl)

2024 spending

$70.7M

Beneficiaries

18,368

149,372 claims

Per beneficiary

$3,847

$9.30 per unit

View as table
YearSpending
2020$139,934,184
2021$119,562,008
2022$105,251,883
2023$95,342,510
2024$70,660,251

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,777 on PubMed

Sponsor: Indivior

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.